GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OTCPK:ONPPF) » Definitions » EV-to-Revenue

Oncopeptides AB (Oncopeptides AB) EV-to-Revenue : 18.67 (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Oncopeptides AB's enterprise value is $68.52 Mil. Oncopeptides AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $3.67 Mil. Therefore, Oncopeptides AB's EV-to-Revenue for today is 18.67.

The historical rank and industry rank for Oncopeptides AB's EV-to-Revenue or its related term are showing as below:

ONPPF' s EV-to-Revenue Range Over the Past 10 Years
Min: -108.85   Med: 18.71   Max: 512.82
Current: 18.22

During the past 10 years, the highest EV-to-Revenue of Oncopeptides AB was 512.82. The lowest was -108.85. And the median was 18.71.

ONPPF's EV-to-Revenue is ranked worse than
66.47% of 1038 companies
in the Biotechnology industry
Industry Median: 7.985 vs ONPPF: 18.22

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-05), Oncopeptides AB's stock price is $0.265. Oncopeptides AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.03. Therefore, Oncopeptides AB's PS Ratio for today is 9.14.


Oncopeptides AB EV-to-Revenue Historical Data

The historical data trend for Oncopeptides AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB EV-to-Revenue Chart

Oncopeptides AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.39 91.28 18.33

Oncopeptides AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.45 21.70 21.52 18.33 15.23

Competitive Comparison of Oncopeptides AB's EV-to-Revenue

For the Biotechnology subindustry, Oncopeptides AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's EV-to-Revenue falls into.



Oncopeptides AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Oncopeptides AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=68.515/3.67
=18.67

Oncopeptides AB's current Enterprise Value is $68.52 Mil.
Oncopeptides AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncopeptides AB  (OTCPK:ONPPF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Oncopeptides AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.265/0.029
=9.14

Oncopeptides AB's share price for today is $0.265.
Oncopeptides AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncopeptides AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB (Oncopeptides AB) Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.